FDA sees bowel risk in early Glaxo vaccine data
WASHINGTON (Reuters) - GlaxoSmithKline Plc's rotavirus vaccine may be linked to a small increase in a life-threatening type of bowel obstruction, U.S. health officials said on Wednesday.
Early data from a study in Mexico suggested infants given the Rotarix vaccine may face a higher chance of an intestinal problem known as intussusception in the 31 days after their first dose, the Food and Drug Administration said on its website.
"Although the results are preliminary and will require further evaluation, FDA approved revised labeling to inform healthcare providers of this finding," the agency said.
Rotavirus is the world's leading cause of severe diarrhea and dehydration in young infants. The benefits of rotavirus vaccines continue to outweigh risks, the FDA said.
Glaxo's rotavirus vaccine sales in 2009 were $440 million globally, including $118 million in the United States.
The British drug company's shares slipped 0.7 percent to $40.06 in morning trading on the New York Stock Exchange.
(Reporting by Lisa Richwine; Editing by Maureen Bavdek)
- Tweet this
- Share this
- Digg this
- U.S. strikes have slowed Iraq militants but not weakened them - Pentagon
- Islamic State video purports to show beheading of U.S. journalist
- UPDATE 1-Pakistan crisis puts army back in the driving seat
- Pakistan crisis puts army back in the driving seat
- Landslides hit Japan's Hiroshima, killing at least 27 |
To try to control the Ebola epidemic spreading through West Africa, Liberia has quarantined remote villages at the epicentre of the virus, evoking the "plague villages" of medieval Europe that were shut off from the outside world. Full Article | Slideshow: Fighting Ebola
From cradle to grave, Japan's Kewpie adapts menu to feed ageing nation. Full Article